Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Kardigan Raises $254M Series B to Advance Cardiovascular Drug Development
Series BVenture Capital

Kardigan Raises $254M Series B to Advance Cardiovascular Drug Development

•October 15, 2025
•Oct 15, 2025
0

Participants

Kardigan

Kardigan

company

T. Rowe Price

T. Rowe Price

investor

ARCH Venture Partners

ARCH Venture Partners

investor

Sequoia Heritage

Sequoia Heritage

investor

Fidelity

Fidelity

investor

Deal Summary

Kardigan closed a $254M Series B to advance its cardiovascular drug development efforts. Lead and participating backers include Fidelity Management & Research Company, accounts advised by T. Rowe Price Investment Management, ARCH Venture Partners and Sequoia Heritage.

0

Comments

Want to join the conversation?

Loading comments...